yes I know they are trying to disrupt. That’s why they’re in every medical journal, held multiple conferences worldwide, have not compared to other products in the market except those that are inferior in sensitivity and specificity, have not disclosed sensitivity and specificity through all stages of CRC as well as AA. However, GG says 1-4 is in the bag. So show the market what you got.
everyone wants to disrupt. Look at the BNPL stocks. So disruptive even when in full operation.
so when are investors going to find out how much RHY will sell the product for and the ACTUAL margin.
Sounds like to me that the board of directors will be out selling the product as well as making strategic decisions.
Hang on, the scientists will start dividing their time between the lab and going to conferences all around the world to tell everyone COLOSTAT is the disrupter of CRC blood tests.
price means nothing if it’s the product that does not have high sensitivity and specificity for AA.
they should announce to market. How can you sell a product without required information to assess the product?
